{"id":"duloxetine-dlx","safety":{"commonSideEffects":[{"rate":"20-25","effect":"Nausea"},{"rate":"10-15","effect":"Dizziness"},{"rate":"10-12","effect":"Somnolence"},{"rate":"8-12","effect":"Dry mouth"},{"rate":"8-10","effect":"Fatigue"},{"rate":"8-10","effect":"Constipation"},{"rate":"5-8","effect":"Decreased appetite"},{"rate":"5-8","effect":"Sweating"},{"rate":"5-10","effect":"Sexual dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the presynaptic reuptake transporters for both serotonin and norepinephrine, leading to increased neurotransmitter concentrations in the synaptic cleft. This dual mechanism is thought to enhance mood regulation and pain modulation, making it effective for both psychiatric and pain-related conditions. The norepinephrine component particularly contributes to analgesic effects.","oneSentence":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:16.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Diabetic peripheral neuropathic pain"},{"name":"Fibromyalgia"},{"name":"Chronic musculoskeletal pain"},{"name":"Stress urinary incontinence"}]},"trialDetails":[{"nctId":"NCT00385671","phase":"PHASE4","title":"An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-09","conditions":"Diabetic Neuropathy, Painful","enrollment":407},{"nctId":"NCT00945945","phase":"PHASE3","title":"A Study of Duloxetine in Patients With Osteoarthritis Knee Pain","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-07","conditions":"Osteoarthritis Knee Pain","enrollment":424}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY248686","Cymbalta"],"phase":"phase_3","status":"active","brandName":"Duloxetine (DLX)","genericName":"Duloxetine (DLX)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites. Used for Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}